Fursultiamine

Fursultiamine is a vitamin B₁ derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine is the antagonist for hepcidin, that inhibits the binding of hepcidin to the iron efflux protein Ferroportin (FPN1), thereby promoting the efflux of intracellular iron. Fursultiamine is also the inhibitor for NF-κB signaling pathway. Fursultiamine can be used for vitamin B1?deficiency, osteoarthritis (OA) and cancer research^[1][2]. In Vitro:Fursultiamine (10 μM, 24 h) inhibits Sorafenib (HY-10201)-induced cell death of HepG2 and Huh7, inhibits the cleavage of caspase-3 and PARP^[3], inhibits NF-κB signaling pathway.
Fursultiamine (100 μM, 12 h) inhibits LPS (HY-D1056)-induced expression of IL-6, IL-8 and MCP-1 in cell ARPE-19^[4].
Fursultiamine (100 μM, 12 h) enhances the mitochondrial respiration, reactivates mitochondrial pyruvate dehydrogenase, and improves the metabolic reprogramming under hypoxia conditions^[4].
In Vivo:Fursultiamine (100 mg/kg, ip for 8 weeks) reduces MMP-1 expression, exhibits chondroprotective efficacy in rabbit osteoarthritis models^[2].
Fursultiamine (50 mg/kg, po, once a day for 7 days) ameliorates laser induced choroidal neovascularization lesions (CNV) in mouse models^[4].